Literature DB >> 2252363

Treatment of spasticity with botulinum toxin: a double-blind study.

B J Snow1, J K Tsui, M H Bhatt, M Varelas, S A Hashimoto, D B Calne.   

Abstract

We studied the effect of botulinum-A toxin on spasticity of the leg adductors in 9 patients who were either chair-bound or bed-bound with chronic stable multiple sclerosis. We injected botulinum toxin (400 mouse units) or placebo into the adductor muscles in a randomized, crossover, double-blind design. Two physicians, who were unaware of the treatment order, used an objective rating scale and independently assessed the patients; interobserver correlation was excellent (r = 0.93-0.81). We found that botulinum toxin produced a significant reduction in spasticity (p = 0.009) and a significant improvement in the ease of nursing care (p = 0.009). There were no adverse effects during this short-term trial. This is the first demonstration of the beneficial effect of botulinum toxin on focal spastic muscle contractions.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2252363     DOI: 10.1002/ana.410280407

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  52 in total

Review 1.  Evidence basis for treatment of spasticity.

Authors:  D M Dawson
Journal:  Curr Neurol Neurosci Rep       Date:  2001-11       Impact factor: 5.081

Review 2.  Management of secondary-progressive multiple sclerosis.

Authors:  Gavin Giovannoni
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

Review 3.  Neurorehabilitation in multiple sclerosis--what is the evidence-base?

Authors:  Jürg Kesselring
Journal:  J Neurol       Date:  2004-09       Impact factor: 4.849

Review 4.  Outcomes assessment of drug treatment in multiple sclerosis clinical trials.

Authors:  M Malone; B Lomaestro
Journal:  Pharmacoeconomics       Date:  1996-03       Impact factor: 4.981

5.  [Botulinum toxin in the treatment of adult spasticity. An interdisciplinary German 10-point consensus 2010].

Authors:  J Wissel; M auf dem Brinke; M Hecht; C Herrmann; M Huber; S Mehnert; I Reuter; A Schramm; A Stenner; C van der Ven; M Winterholler; A Kupsch
Journal:  Nervenarzt       Date:  2011-04       Impact factor: 1.214

6.  Does reducing spasticity translate into functional benefit? An exploratory meta-analysis.

Authors:  H P Francis; D T Wade; L Turner-Stokes; R S Kingswell; C S Dott; E A Coxon
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-11       Impact factor: 10.154

Review 7.  Botulinum toxin in multiple sclerosis.

Authors:  Wolfgang H Jost
Journal:  J Neurol       Date:  2006-02       Impact factor: 4.849

8.  The therapeutic effects of ablative neurosurgical procedures on the spinal cord for intractable spinal spasticity.

Authors:  Bunpot Sitthinamsuwan; Pornchai Khumsawat; Luckchai Phonwijit; Sarun Nunta-Aree; Akkapong Nitising; Sirilak Suksompong
Journal:  Spinal Cord Ser Cases       Date:  2017-06-08

Review 9.  Botulinum toxin for symptomatic therapy in multiple sclerosis.

Authors:  Michelle H Cameron; Francois Bethoux; Nina Davis; Meredith Frederick
Journal:  Curr Neurol Neurosci Rep       Date:  2014-08       Impact factor: 5.081

10.  The Use of Botulinum Toxin Type A in Headache Treatment.

Authors:  Ninan T. Mathew; Alex O. Kaup
Journal:  Curr Treat Options Neurol       Date:  2002-09       Impact factor: 3.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.